why choose us

First received: January 19, 2023

Clinical Trial: CD8 Minibody Repeatability Study

Study Status: Completed

Recruit Status: RECRUITING

Condition: Melanoma

Study Type: INTERVENTIONAL


Official Title: Positron Emission Tomography Repeatability Evaluation of Tissue Zirconium 89Zr Crefmirlimab Berdoxam

Brief Summary: Zr-89 crefmirlimab berdoxam is a Zirconium-89 labelled minibody developed by ImaginAb for full body PET imaging of CD8+ cell distribution (CD8 ImmunoPET).The primary objective of this study is to assess the test-retest repeatability of CD8 immunoPET imaging in oncology patients with stable disease.

Read more